3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
3
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
tislelizumab
1
spartalizumab
1
sintilimab
1
milademetan
1
enzalutamide
1
Pemetrexed
1
Midazolam
1
Letrozole
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fulvestrant
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Midazolam
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled